On-demand: featuring presentation and speaker Q&A: Dr Marieke Vollebergh, Prof Dr Alwin Krämer and Dr Claire Mitchell will discuss the new care pathways for CUP patients in development – what are the differences and what can be learnt from other health systems. Part of the World CUP Awareness Week, this webinar is specifically created to share the latest updates with both clinicians and patients, including oncologists, pathologists, nurses and researchers, plus patients, their families and patient advocates.
World Cup Awareness Week is supported by Missie Tumor Onbekend and Sarah Jennifer Knott Foundation.
Also available on-demand:
Watch this online international event from the comfort of your own home
Packed with inspiring different CUP care pathways that are available to patients across Europe:
Gain three very different insights into CUP care: what can be learned from other health systems?
|
Introduction and instructions
Warnyta Minnaard, Co-founder Missie Tumor Onbekend
|
|
|
Clinical CUP diagnostics and care pathways: differences across Europe
Presented by: Dr Marieke Vollebergh, Internist, Netherlands Cancer Institute, The Netherlands; Prof Dr Alwin Krämer, Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Germany; Dr Claire Mitchell, Consultant in Medical Oncology, Clinical lead for Acute Oncology and CUP services at Central Manchester Foundation Trust, UK
|
|
|
Questions and answers with the speakers
Led by: Prof Dr Alwin Krämer, German Cancer Research Center
|
Your expert speakers
Marieke started working on her PhD research at the Netherlands Cancer Institute in 2007, investigating whether certain DNA characteristics could predict sensitivities to certain types of chemotherapy. Marieke started working as medical oncologist in 2019 and mainly deliver care to patients with gastrointestinal cancer; primarily those with esophageal cancer, stomach cancer, or colon cancer that has spread to the liver. At the Netherlands Cancer Institute they have a highly specialized and dedicated team of radiation therapists and surgeons, ready to find the treatment plan that best fits every patient. This collaboration, the commitment of the entire team, and the ability to implement always increasing knowledge (even about the smallest cellular levels) through research - most of which is conducted at the Netherlands Cancer Institute itself - makes her work at the institute unique and exciting.
Born in Germany, Alwin began his career studying Medicine at the University of Mainz, Germany and Bern, Switzerland. His training took him international with a residency at University of Heidelberg, a postdoctoral fellow in Wisconsin, USA and a Heisenburg fellow at the Danish Cancer Society Research Center, Copenhagen, Denmark.
From 2005, Alwin has dedicated his time and research to Hematology, which has led him to be both the Co-chairman of the Steering Committee „CUP-Syndrome” of the Arbeitsgemeinschaft Internistische Onkologie (AIO) within the German Cancer Society (DKG) and since 2022 the Chairman of the ESMO CUP-Practice Guidelines Committee.
During his career, Alwin has been awarded the Heisenberg Stipend of the German Research Society (DFG), Vincenz-Czerny Award of the Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) and in 2010 the Science Award of the Arbeitsgemeinschaft Internistische Onkologie (AIO) within the German Cancer Society (DKG).
Dr Mitchell graduated from the Royal London and St Bartholomew's Medical College (University of London) in 1999 and entered Specialist Training in Medical Oncology in Manchester (at The Christie) in 2005, completing in 2013. She completed her PhD in "Imaging and Angiogenesis" at the University of Manchester in 2010. In addition to completion of Specialist Training in Medical Oncology, Dr Mitchell has completed a postgraduate diploma in Palliative Medicine. She was appointed Consultant in Medical Oncology at The Christie in 2013.
Since being appointed as a consultant Dr Mitchell has been an active member of the acute oncology network group helping to develop acute oncology services and CUP services throughout the region. Following the formation of Manchester Cancer in January 2014, Dr Mitchell was appointed as the Pathway Director for Acute Oncology, overseeing service development of acute oncology services and training in the region.
Dr Mitchell is an active participant in the gynaecological medical oncology group in service development and the expansion of disease-specific clinical trials portfolio. She has led the establishment of the Cancer of Unknown Primary service at The Christie as a site-specific group with development of trials within it. Dr Mitchell has a continuing role in the educational provision for junior trainees based at The Christie and within the broader network.
Supporting NHS professionals with free, practical content
